These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9380259)

  • 41. Oxidation reactions in Parkinson's disease.
    Olanow CW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 32-7; discussion 37-9. PubMed ID: 2215972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death.
    Mertens B; Varcin M; Michotte Y; Sarre S
    Eur J Neurosci; 2011 Oct; 34(7):1141-8. PubMed ID: 21936877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
    Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
    Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results.
    Kirik D; Björklund A
    Brain; 2005 Jul; 128(Pt 7):1478-9. PubMed ID: 15980119
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron in brain function and dysfunction with emphasis on Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Eur Neurol; 1991; 31 Suppl 1():34-40. PubMed ID: 1649757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.
    Hirsch EC
    Mol Neurobiol; 1994; 9(1-3):135-42. PubMed ID: 7888089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The role of neuromelanin in Parkinson's disease--new concepts].
    Stepień K; Dzierzega-Lecznar A; Tam I
    Wiad Lek; 2007; 60(11-12):563-9. PubMed ID: 18540183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of neuromelanin on oxidative pathways within the human substantia nigra.
    Double KL; Ben-Shachar D; Youdim MB; Zecca L; Riederer P; Gerlach M
    Neurotoxicol Teratol; 2002; 24(5):621-8. PubMed ID: 12200193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Free radicals and their scavengers in Parkinson's disease.
    Yoshikawa T
    Eur Neurol; 1993; 33 Suppl 1():60-8. PubMed ID: 8375435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
    Kienzl E; Jellinger K; Stachelberger H; Linert W
    Life Sci; 1999; 65(18-19):1973-6. PubMed ID: 10576448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxygen, antioxidants and brain dysfunction.
    Choi BH
    Yonsei Med J; 1993 Mar; 34(1):1-10. PubMed ID: 8379180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems.
    Zareba M; Bober A; Korytowski W; Zecca L; Sarna T
    Biochim Biophys Acta; 1995 Jun; 1271(2-3):343-8. PubMed ID: 7605801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuromelanin and nigrostriatal dopamine neuron degeneration.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1993 May; 60(5):1976-7. PubMed ID: 8473913
    [No Abstract]   [Full Text] [Related]  

  • 58. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.
    Maruyama W; Shamoto-Nagai M; Akao Y; Riederer P; Naoi M
    J Neural Transm Suppl; 2006; (70):125-32. PubMed ID: 17017519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding Parkinson's disease.
    Youdim MB; Riederer P
    Sci Am; 1997 Jan; 276(1):52-9. PubMed ID: 8972618
    [No Abstract]   [Full Text] [Related]  

  • 60. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?
    Halliwell B
    Acta Neurol Scand Suppl; 1989; 126():23-33. PubMed ID: 2694733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.